On September 6, 2018, the Iowa Medical Cannabidiol Board received a Petition for Addition of Ganglioglioma to the list of debilitating medical conditions for which the medical use of cannabidiol would be medically beneficial. At a duly noticed meeting on November 2, 2018, the Iowa Medical Cannabidiol Board considered, pursuant to Iowa Code section 124E.5(3) and Iowa Administrative Code 641—154.65, the Petition. Board members Dr. Ken Cheyne, Dr. Jill Liesveld, Cpt. Mike McKelvey, Dr. Lonny Miller, Dr. Bob Shreck, Dr. Wendy Zadeh, Dr. Stephen Richards and Dr. Jacqueline Stoken were present at the meeting in person when the Petition was considered. The Petitioner did not appear at the November 2, 2018, meeting. The record includes the Petition and all information presented and discussed at the November 2, 2018, meeting.

The Iowa Medical Cannabidiol Board, after reviewing the record, voted 8 – 0 to DENY the Petition. Pursuant to 641 IAC 154.65(8), the Board issues the following Findings and Order.
FINDINGS:

1. The Petition to Add Ganglioglioma as a debilitating medical condition for which the medical use of medical cannabidiol would be medically beneficial was properly filed in the Office of Medical Cannabidiol within the Iowa Department of Public Health.

2. The Iowa Medical Cannabidiol Board has jurisdiction to accept and review the Petition to Add Ganglioglioma as a debilitating medical condition for which the medical use of medical cannabidiol would be medically beneficial pursuant to Iowa Code chapter 124E.

3. Recommendations of the Iowa Medical Cannabidiol Board regarding the addition of medical conditions to the list of debilitating medical conditions for which the medical use of cannabidiol would be medically beneficial shall be made to the Iowa Board of Medicine for consideration, and if approved by the Iowa Board of Medicine, shall be adopted by the Iowa Board of Medicine by rule pursuant to Iowa Code section 124E.5(4).

4. Petitioner requested that the Iowa Medical Cannabidiol Board recommend the Addition of Ganglioglioma as a debilitating medical condition for which the medical use of medical cannabidiol would be medically beneficial.

5. Petitioner was offered an opportunity to present information to the Iowa Medical Cannabidiol Board at its meeting on November 2, 2018.

6. Ganglioglioma is a rare type of benign brain tumor.

7. Evidence-based medical literature indicating that the medical use of cannabidiol would be medically beneficial for patients diagnosed with Ganglioglioma is
lacking.

8. The Petition indicated the petitioner experienced Untreatable Pain as a result of the Ganglioglioma diagnosis.

9. Untreatable Pain is listed as a Debilitating Medical Condition for which the medical use of cannabidiol would be medically beneficial in Iowa Code section 124E.2(3)"e".

10. Untreatable Pain is defined in Iowa Code section 124E.2(8) as "any pain whose cause cannot be removed and, according to generally accepted medical practice, the full range of pain management modalities appropriate for the patient has been used without adequate result or with intolerable side effects."

11. Patients diagnosed with Ganglioglioma may experience pain whose cause cannot be removed.

12. Patients diagnosed with Ganglioglioma may qualify for certification of Untreatable Pain as a debilitating medical condition for purposes of Iowa Code chapter 124E when, according to generally accepted medical practice, the full range of pain management modalities appropriate for the patient has been used without adequate result or with intolerable side effects.

ORDER:

The Iowa Medical Cannabidiol Board hereby denies the petition for the addition of Ganglioglioma to the list of debilitating medical conditions for which the medical use of cannabidiol would be medically beneficial. Patients diagnosed with Ganglioglioma may seek certification of Untreatable Pain as a debilitating medical condition for which the medical use of cannabidiol would be medically beneficial
and therefore addition of Ganglioglioma as a debilitating medical conditions for which the medical use of cannabidiol would be medically beneficial is not necessary.

Mike McKelvey

By: Cpt. Mike McKelvey, Chairperson

March 8, 2019

Date